出版社：Centre for Innovation Law and Policy at the University of Toronto, Faculty of Law
摘要：In June of 2004, Eliot Spitzer, Attorney General of the State of New
York, filed a lawsuit against GlaxoSmithKline for ¡°fraud by misrepresentation,
concealing and otherwise failing to disclose¡± to physicians
important information related to the safety and efficacy of its top-selling
anti-depressant Paxil. Allegedly, GlaxoSmithKline withheld information
on five clinical trials conducted with Paxil in the 1990s that
failed to demonstrate efficacy and indicated an increased risk of agitation
and suicidal thoughts and behavior in children and adolescents.
Furthermore, allegedly, the company embarked on a campaign
to promote the drug on misleading information by not disclosing all
the findings. Sales representatives were allegedly encouraged to
distribute copies of a scientific article that discussed a carefully
screened selection of positive results of only one study. The lawsuit
by the Attorney General was settled out of court after laxoSmithKline
agreed to pay a fine and to set up a website to publicize all the
results of its clinical trials. But a class-action lawsuit has now been
launched on behalf of people whose children have allegedly died or
been seriously harmed as a result of taking the drug.
